The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Federal health agencies including the NIH, FDA, and CDC laid off over 10,000 employees following a Supreme Court ruling.

Infant vaccination rates improved from 2023 to 2024, but millions of infants still do not receive routine vaccination.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

OSA in US active-duty military personnel is linked to increased risk for adverse psychological and physical health outcomes and more health care use.

A resident of Northern Arizona recently died after being infected with the pneumonic plague, the first death in the US since 2007.

The FDA sent letters instructing companies to stop their marketing of concentrated 7-OH, a compound found in kratom.

Digital inhalers can detect significant changes in physiologic and inhaler use metrics in the 14 days before COPD exacerbations.

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.